Global Transdermal Scopolamine Industry

Global Transdermal Scopolamine Industry

  • April 2021 •
  • 103 pages •
  • Report ID: 6044349 •
  • Format: PDF
Abstract:
- Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027
- Amid the COVID-19 crisis, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the period 2020-2027.
- The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR
- The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

- Select Competitors (Total 41 Featured) -
  • Alchem International
  • Alkaloids of Australia
  • ALZA Corporation
  • Baxter International Inc.
  • Caleb Pharmaceuticals Inc
  • Centroflora-Cms
  • Fine Chemicals Corporation
  • GlaxoSmithKline Plc
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Co. Plc
  • Phytex Australia